These findings collectively suggest that sEH inhibition with t-AUCB holds therapeutic promise for alleviating cognitive deficits associated with type 2 diabetes through multiple molecular mechanisms. This evidence concerns the gene EPHX2 and type 2 diabetes mellitus.